Special Articles

Organic Impurities present in Pharmaceuticals and Food Products

Poonam Kushwaha

Poonam Kushwaha

TheOrganic Impurities in Pharmaceuticals:

The impurities in drug are unwanted chemicals that remains with the active pharmaceutical ingredients (API), develop during formulation and upon aging of API/drug products.The presence of these unwanted chemicals even in trace amount may influence the efficacy and safety of pharmaceutical products.

These impurities often posses unwanted pharmacological or toxicological effects by which any benefits from their administration may be outweighed [1].

Preparation of 2-Aminobenzothiazole Derivatives : A Review

Vikash Kumar

Vikash Kumar

The present review focus on synthesis of various 2-aminobenzothiazoles derivatives by cyclizing the arylthioureas, 2-aminothiophenol and substituted anilines with the help of different catalysts or agents.

Chloroformamidinium Salts; latest and efficient reagent for preparation of 2-aminobenzothiazole derivatives.

Design of Experiments for Pharmaceutical Formulation Development

Mr.Kirupakar .B.R

Kirupakar .B.R

Design of experiments (DOE) is a useful tool for determining specific factors affecting defect levels in a product.

During the 1920s, a British statistician named Ronald Fisher put the finishing touches on a method for making breakthrough discoveries. Some 70 years later, Fisher's method, now known as design of experiments, has become a powerful software tool for engineers and researchers.

But why did it take engineers so long to begin using DOE for innovative problem solving? After all, they were ignoring a technique that would have produced successes similar to the following modern-day examples:

The Microsponge Drug Delivery System : For Delivering an Active Ingredient by Controlled Time Release

John I. D’souza

John I. D’souza

The expanding arena of emerging drugs, increased sensitivity to clinical
outcomes and healthcare costs are driving the need for alternative drug delivery
methods and devices.

The drug delivery technology landscape has become highly competitive and
rapidly evolving. More and more developments in delivery systems are being
integrated to optimize the efficacy and cost-effectiveness of the therapy.
New classes of pharmaceuticals, biopharmaceuticals (peptides, proteins and
DNA-based therapeutics) are fueling the rapid evolution of drug delivery technology.
These new drugs typically cannot be effectively delivered by conventional
means. The benefits from targeted, localized delivery of therapeutic agents
are other driving forces for the market.

Peroral Delivery Of Peptide Through Superporous Hydrogel : A Review

Swarnali Das

Swarnali Das

Peptide and protein drugs have found an important position in therapeutics.

Many protein- and DNA-based drugs exhibit high sensitivity to the surrounding
physiological conditions as a result of their delicate physicochemical characteristics
and the susceptibility to degradation by proteolytic enzymes in biological fluids.
So, they need to be properly protected during administration and their release
needs to be precisely targeted and controlled.

Patent System in the Pharmaceutical Industry

O.A.Thusleem

O.A.Thusleem

The pharmaceutical sector is a major user of the patent system.

While only a small - and declining - number of new chemical entities are approved annually, thousands of patents are applied for to protect variants of existing products, processes of manufacture or, where admitted, second indications of known pharmaceutical products. Since patents confer exclusive rights regarding the production, sale and use of the patented subject matter, they can be used to restrain competition and set prices higher than those that would have existed if competitive products were available. This is the very purpose of the patent system, which is generally justified as necessary to encourage investments to develop new products and processes.1

New Hope For Mechanism Based Treatment Of Parkinson’s Disease

Talha jawaid

Talha jawaid

Researchers have discovered that rifampicin, an antibiotic used to treat tuberculosis and leprosy, inhibit the formation of alpha synuclein fibrils that have already formed.

Because the aggregation of alpha synuclein in dopaminergic neuron is critical steps in pathogenesis of Parkinson’s disease (PD). Rifampicin or a related compound could provide a new approach to the treatment of PD. 1

Alpha-Synuclein And Parkinsons Disease

PD is a common neurodegenerative disease disorder caused by the progressive loss of dopaminergic neurons in the substantia nigra.Current treatment is symptomatic- patients are usually given levodopa to improve motor symptoms.

Lantana Camara Linn. (Raimuniya) : A Noxious Weed Having Pivotal Importance In Therapeutics

Dwivedi S

Sumeet Dwivedi

Lantana camara Linn. is a significant weed of which there are some 650 varieties in over 60 countries or island groups.

It is established and expanding in many regions of the world, often as a result of clearing of forest for timber or agriculture. It impacts severely on agriculture as well as on natural ecosystems. The plants can grow individually in clumps or as dense thickets, crowding out more desirable species. In disturbed native forests it can become the dominant understorey species, disrupting succession and decreasing biodiversity. Being the noxious nature of the weed, it is used in the treatment of various ailments. The present paper reviews the phytochemical profile and therapeutic efficacy of the plant.

Me-Too Drugs - A Tiny Revolutionize

Vikash Kumar

Vikash Kumar

What are “Me-Too” Drugs? 1, 2 : The Process of new drug development is complicated, time-consuming and expensive.

In modern chemotherapy, when drugs were discovered and developed through the process of screening thousands of molecules for a variety of disease conditions, using animal models, there has been a growing criticism that too many molecules were developed with similar chemical structure and the same pharmacological profile, with very little to distinguish them from each other in terms of their therapeutic utility.